News of Note—GlaxoSmithKline, VLP Therapeutics and more


Here is some other vaccine news of note for the week:

> GlaxoSmithKline's vaccine sales grew 16% last year to £5.9 billion ($7.64 billion). Shingrix sales hit £784 million ($1 billion) in its first full year on the market. Release

> Gaithersburg, Maryland-based VLP Therapeutics said it plans to kick off an initial clinical study of its malaria vaccine candidate. Release


Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

> Officials in Kentucky are looking into vaccine-associated infections in Kentucky, Ohio and Indiana due to possible improper handling and storage by a service provider. Release (PDF)


Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.